An Illustrated Look at Cronos Group Following their Q3 Earnings

As a follow up to our quick take this morning on Cronos Group (TSX: CRON, NASDAQ: CRON), we thought it would be helpful to share an illustrated look at Cronos Q3 earnings.

Cronos effectively doubled their cannabis output since Q2, selling 3,100 kg of dried gram cannabis equivalents. That’s about half of Aphria’s most recent quarterly unit sales and a sixth of Aurora’s.

Inventory is climbing steadily. The low BA total may represent the quarter’s end catching the grow rooms between cycles.
Cronos still lags other mid tier cultivators in unit sales…
…but they’re catching up

Yet, Cronos’ enterprise value is nearly identical to Aphria’s, and less than a third of Aurora’s. Whether this apparent value gap is tradeable is a matter of opinion, but few would argue with the notion that its roots are in Cronos’ financial position, relative to its peers, and in its backers.

Cronos has $1.92 billion in cash. That’s more than half of its market cap. The company carries no debt. The cash originated in the $2.4 billion equity investment made by US tobacco giant Altria this past December. Altria plans to use Cronos as its cannabis platform globally.

The tobacco business isn’t going anywhere and, more to the point, they have the background and understanding to make this particular type of consumer goods business work.

Cronos does not appear to be bothered by the fact that, among the unicorn-class Canadian cultivators, they have the smallest unit sales. Part of that is the strong growth, but it’s entirely possible that their US backers don’t expect this business to succeed as a Canadian cultivator. Altria may be content to use Canada as a sort of R&D lab. The retail footprint from their tobacco division can be considered a far better head start in the US market than all of the MSO front runners put together. From Altria’s perspective, the key to success in a US cannabis landscape that allows them to participate may well be the consumer product knowledge that they gain from their Cronos experiment.


Information for this analysis was found via Sedar and Cronos Group. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Moon River Moly: The Davidson Moly-Copper-Tungsten PEA

Integra: The DeLamar Heap Leach Feasibility Study

Highlander Silver: The Saviour Of Bear Creek Mining

Recommended

Steadright Expects To Receive Mining License For New Copper Valley Project Within The Next Month

Goliath Resources Hits 19.13 g/t Gold Over 6.10 Metres At Surebet In Final 2025 Gold Assays

Related News

Cronos Group Posts Revenues of US$7.3 Million For Q4 2019, Loss of US$63.8 Million

Cronos Group (TSX: CRON) (NASDAQ: CRON) has finally reported its fourth quarter and full fiscal...

Monday, March 30, 2020, 04:36:32 PM

Ginkgo Bioworks To Go Public Via SPAC Route With Soaring Eagle Acquisition Corp

It appears that Cronos Group (TSX: CRON) (NASDAQ: CRON) might be losing its star player....

Tuesday, May 11, 2021, 10:30:00 AM

Look for Constellation to Write Off Significant Amount of Canopy Investment

On October 30 2017, Constellation Brands (NYSE: STZ) and Canopy Growth Corp. (NASDAQ: CGC) jointly...

Thursday, August 25, 2022, 10:10:00 AM

Lord Jones! Cronos Group Generates Positive Net Income Thanks to Declining Share Price

This morning Cronos Group (TSX: CRON, NASDAQ: CRON) reported their third quarter results. We organized...

Tuesday, November 12, 2019, 10:32:28 AM

Cronos Group To Spend US$67 Million In Cash Acquiring European Adult-Use Firm

Evidently M&A activity is still occurring in the cannabis sector, with Cronos Group (TSX: CRON)...

Tuesday, December 9, 2025, 08:58:22 AM